The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion

• Published in: The Journal of clinical investigation Vol. 84; no. 3; pp. 728 - 732
• Main Authors: BROWN, A. J, RITTER, C. R, FINCH, J. L, MORRISSEY, J, MARTIN, K. J, MURAYAMA, E, NISHII, Y, SLATOPOLSKY, E
• Format: Journal Article
• Language: English
• Published: Ann Arbor, MI American Society for Clinical Investigation 01.09.1989
• Subjects: Animals; Biological and medical sciences; Calcitriol - administration & dosage; Calcitriol - analogs & derivatives; Calcitriol - pharmacology; Calcium - blood; Cells, Cultured; Injections, Intraperitoneal; Male; Medical sciences; Miscellaneous; Parathyroid Glands - metabolism; Parathyroid Glands - secretion; Parathyroid Hormone - antagonists & inhibitors; Parathyroid Hormone - biosynthesis; Parathyroid Hormone - secretion; Pharmacology. Drug treatments; Protein Precursors - biosynthesis; Rats; Rats, Inbred Strains; RNA, Messenger - biosynthesis; Cell culture; Calcium; Rat; Secretion; Rodentia; Biosynthesis; Metabolism; In vitro; Biological activity; In vivo; Vertebrata; Mammalia; Parathyroid hormone; Animal; Parathyroid glands; Mechanism of action

1,25-Dihydroxyvitamin D (1,25-(OH)2D3) directly suppresses the secretion and synthesis of PTH in vivo and in cell culture. This compound has been used to treat secondary hyperparathyroidism associated with renal failure, but in some patients prolonged treatment with 1,25-(OH)2D3 results in hypercalc...